跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

SML0900

Sigma-Aldrich

ZLN024

≥98% (HPLC)

别名:

2-[[2-(2-Bromo-4-methylphenoxy)ethyl]thio]-pyrimidine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H13BrN2OS
分子量:
325.22
UNSPSC代码:
12352202
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 20 mg/mL, clear

储存温度

2-8°C

InChI

1S/C13H13BrN2OS/c1-10-3-4-12(11(14)9-10)17-7-8-18-13-15-5-2-6-16-13/h2-6,9H,7-8H2,1H3

InChI key

KWJRSHZSULRJHE-UHFFFAOYSA-N

生化/生理作用

ZLN024 is an allosteric activator of AMPK hetero-trimers. The compound ZLN024 protects against dephosphorylation of Thr172, which is critical for activity, and antagonizes AMPK autoinhibition. ZLM024 improves glucose tolerance and lowers total cholesterol levels in db/db mice.

象形图

CorrosionExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tereza Moore et al.
PloS one, 15(10), e0240517-e0240517 (2020-10-15)
Mitochondrial diseases are a clinically heterogenous group of disorders caused by respiratory chain dysfunction and associated with progressive, multi-systemic phenotype. There is no effective treatment or cure, and no FDA-approved drug for treating mitochondrial disease. To identify and characterize potential

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门